BioCryst Pharmaceuticals, Inc.
BCRXBioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
Drugs in Pipeline
18
Phase 3 Programs
6
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
BCX4161
Hereditary Angioedema
BCX7353 capsules
Hereditary Angioedema, HAE
Peramivir
Influenza
Berotralstat
Hereditary Angioedema
Oseltamivir
Influenza
BCX7353
Hereditary Angioedema (HAE)
Peramivir 150 mg
Influenza
forodesine hydrochloride
Lymphoma
BCX-1777
Leukemia, Lymphocytic
forodesine hydrochloride (BCX-1777)
Leukemia, T-Cell
Ulodesine (BCX4208) 5 mg
Gout
BCX9930
Paroxysmal Nocturnal Hemoglobinuria
Allopurinol
Gout
Peramivir 200 mg
Influenza
BCX4208
Gout
Forodesine 200 mg
Cutaneous T-cell Lymphoma (CTCL),
ulodesine
Gout
forodesine HCl
Chronic Lymphocytic Leukemia (CLL)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BCX4161 | Phase 3 | Hereditary Angioedema | - | - |
BCX7353 capsules | Phase 3 | Hereditary Angioedema, HAE | - | - |
Peramivir | Phase 3 | Influenza | - | - |
Berotralstat | Phase 3 | Hereditary Angioedema | - | - |
Oseltamivir | Phase 3 | Influenza | - | - |
BCX7353 | Phase 3 | Hereditary Angioedema (HAE) | - | - |
Peramivir 150 mg | Phase 2 | Influenza | - | - |
forodesine hydrochloride | Phase 2 | Lymphoma | - | - |
BCX-1777 | Phase 2 | Leukemia, Lymphocytic | - | - |
forodesine hydrochloride (BCX-1777) | Phase 2 | Leukemia, T-Cell | - | - |
Ulodesine (BCX4208) 5 mg | Phase 2 | Gout | - | - |
BCX9930 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Allopurinol | Phase 2 | Gout | - | - |
Peramivir 200 mg | Phase 2 | Influenza | - | - |
BCX4208 | Phase 2 | Gout | - | - |
Forodesine 200 mg | Phase 2 | Cutaneous T-cell Lymphoma (CTCL), | - | - |
ulodesine | Phase 2 | Gout | - | - |
forodesine HCl | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BioCryst Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in BioCryst Pharmaceuticals, Inc.'s (BCRX) pipeline across Phase 3, Phase 2. Its lead program is BCX4161 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioCryst Pharmaceuticals, Inc.'s next FDA catalyst?→
BioCryst Pharmaceuticals, Inc.'s (BCRX) next tracked catalyst is a Earnings expected November 2, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCRX biotech catalysts?→
Add BCRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioCryst Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.